International Immunopharmacology · 2024 · 12 citations · 38 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer BiomarkersCancer ImmunotherapyCancer TranscriptomicsImmune Cell InfiltrationImmune Checkpoint RegulationImmuno-oncology BiomarkersColon Cancer Adjuvant TherapyImmune Checkpoint BiomarkersImmune Infiltration Prognostic SignaturesImmunosuppressive MicroenvironmentKaplan-meier Confidence IntervalsSingle-cell Rna SequencingTumor Immune Microenvironment ProfilingTumor Microenvironment Biomarkers
BACKGROUND: Siglec9 has been identified as an immune checkpoint molecule on tumor-associated macrophages (TAMs). Nevertheless, the expression profile and clinical significance of Siglec9 + TAMs in colon cancer (CC) are still not fully understood. METHODS: Two clinical cohorts from distinct medical centers were retrospectively enrolled. Immunohistochemistry and immunofluorescence were conducted to evaluate the infiltration of immune cells. Single-cell RNA sequencing and flow cytometry were utilized to identify the impact of Siglec9 + TAMs on the tumor immune environment, which was subsequently validated through bioinformatics analysis of the TCGA database. Prognosis and the benefit of adjuvant chemotherapy (ACT) were also evaluated using Cox regression analysis and the Kaplan-Meier method. RESULTS: High infiltration of Siglec9 + TAMs was associated with worse prognosis and better benefit from 6-month ACT. Siglec9 + TAMs contributed to immunoevasion by promoting the infiltration of immunosuppressive cells and the dysfunction process of CD8 + T cells. Additionally, high infiltration of Siglec9 + TAMs was associated with the mesenchymal-featured subtype and overexpression of the VEGF signaling pathway, which was validated by the strongest communication between Siglec9 + TAMs and vascular endothelial cells. CONCLUSIONS: Siglec9 + TAMs may serve as a biomarker for prognosis and response to ACT in CC. Furthermore, the immunoevasive contexture and angiogenesis stimulated by Siglec9 + TAMs suggest potential treatment combinations for CC patients.
38
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Andrea Cercek, Melissa Lumish, Jenna Sinopoli et al. · New England Journal of Medicine · 2022 · 1.5K citations · Full text
Pan-cancer single-cell landscape of tumor-infiltrating T cells
Liangtao Zheng, Shishang Qin, Wen Si et al. · Science · 2021 · 1.4K citations
Medicine, Immunology, Oncology +17